drugset / Trial / NCT00367432

A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures

NCT00367432

Phase 3 Completed 398 enrolled UCB Japan Co. Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This study is planned to evaluate the safety and efficacy of L059 (levetiracetam) in long-term administration in patients who completed N01020 \[NCT00160165\] or N01221 \[NCT00280696\].

Timeline

Start
2006-07
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified 500 mg Oral
Subject Levetiracetam Other / unclassified 3000 mg Oral

Indications